Aurobindo Pharma Limited is propagating its business in researching, developing, manufacturing, and selling of several pharmaceutical products in India. Producing a significant variation in oral and injectable generic formulations, and active pharmaceutical ingredients and manufacturing peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries.
Along with providing custom research and producing services to biotech and pharmaceutical community the company is reigning over antibiotic, anti-retroviral, cardiovascular, central nervous system, gastroenterological, anti-diabetic, and anti-allergy areas. Besides that, the company is manufacturing proteins, vitamins, minerals, and supplements, sports drinks etc.
The company is exporting its products to almost 150 countries, including the U.S. and Europe along with serving multinational companies. The company is amongst the largest producers of Ampicillin and Cloxacillin in India. Aurobindo Pharma Limited was established in 1986 as a private limited company and headquartered in Hyderabad, Andhra Pradesh, India.
About Company Information:
Aurobindo Pharma was converted to a public limited firm in the year of 1992, after six years from its inception. The company built A CMIC chloride manufacturing unit at Pashamylaram near Hyderabad in the same year. The company started to issue bonus shares in a ratio of 1:1, 2:1 and 7:20 in ’92, ’93 and ’94 respectively. In 1993 the company built up another two plants at Bollaram and Kukatpally near Hyderabad. In 1994, the company increased the capacity at Pondicherry Unit from 204 TPA to 300 TPA along with increasing the installed capacity of its Bollaram unit from 78 TPA to 84 TPA. An amalgamation took place between the company and Chaitanya Organics Pvt. Ltd. in April 1994.
Glaxo (India), a subsidiary of the U.K. based multinational Glaxo went for an alliance with Aurobindo Pharma in 1997, which increased the number of capsules and bulk drug up to 300 million and 840 tons respectively. In 1998, the company introduced Auronim Suspension in its pediatric segment. In FY 1999-2000, the company added a large section of Cephalosporins (Oral & Sterile) and anti-viral along with macrolides, quinolones, semi-synthetic penicillin, formulating for both the domestic and export market.
During 2001-02 79% stake in Ranit Pharma Company were acquired by Aurobindo Pharma Ltd. A 50:50 joint venture firm of the company, namely Citadel Aurobindo Biotech Ltd, launched Aztreonam, a Monabactam Beta-lactam antibiotics as a debut in the Indian Pharma Market, TREONAM being the brand name, in 2003. In 2005-06, the company intervened in the markets of USA & Europe, with participation in the PEPFAR program, initiated by the US Govt. In March 2007, the FDA (U.S.) finally approved the company’s Didanosine Oral Suspension (Pediatric Powder) 10 mg/ml.
Aurobindo Pharma acquired Moore and Carmiooro, the high profile OTC brands from TAD in 2008. AstraZeneca, a leading biopharmaceutical company in the international market, had gone for an agreement with Aurobindo Pharma, for supplying solid dosage and sterile products in 2010. A deal took place between Aurobindo Pharma and National Pharmaceutical Group Corporation, China, for launching the subsidiary Aurobindo (Datong) BioPharma Co Ltd, China (ADBPL).
In April 2014, Aurobindo Pharma declared the completion of several business operations of Europe’s Actavis plc, an internationally recognized pharmaceutical company, manufacturing and supplying generic, brand and biosimilar products. On November 2016, a subsidiary of Aurobindo Pharma Ltd in France, namely Arrow Generiques SAS, signed an agreement to gain the right, title and interest in its products Calcium and Calcium Vitamin D3 in the French market, including the use of Teva Pharmaceutical Industries OROCAL trademark.
On January 2017, Aurobindo Pharma declared about setting up a binding agreement by and through its solely owned subsidiary, Agile Pharma B.V., Netherlands, for acquiring Generis Farmaceutica SA, a pharmaceutical company of Portugal, against a lump sum of 135 million Euro totally including net working capital of 21.7 million Euro. On February 2017, four-cell culture derived biosimilar products from T.L. Biopharmaceutical AG were acquired by Aurobindo Pharma as declared by the company.
How Aurobindo Pharma Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
Aurobindo Pharma Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
Aurobindo Pharma Ltd, Competitors and Sector Peers:
Aarey Drugs & Pharmaceuticals Ltd. AARDRU
Aayush Food & Herbs Ltd. AAYFOO
ABL Bio-Technologies Ltd. ABLBIO
Addlife Pharma Ltd. ADDPHA
Bafna Pharmaceuticals Ltd. BAFPHA
Bajaj Healthcare Ltd. BAJHEA
Brooks Laboratories Ltd. BROLAB
Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
Divi's Laboratories Ltd. DIVIL
Dr. Reddy's Laboratories Ltd. DR
Dujohn Laboratories Ltd. DUJLAB
Earum Pharmaceuticals Ltd.
Elder Health Care Ltd. ELDHEA
Elder Pharmaceuticals Ltd. ELDPHA
Elegant Pharmaceuticals Ltd. ELEPHA
Gennex Laboratories Ltd. GENLAB
Genomics Biotech Ltd. GENBIO
GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
Glenmark Pharmaceuticals Ltd. GLEPHL
IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
JK Pharmachem Ltd. JKPHAL
Jubilant Life Sciences Ltd. JUBILO
Jupiter Bioscience Ltd. JUPIBI
Novartis India Ltd. NOVAIN
Ortin Laboratories Ltd. ORTLAB
Piramal Enterprises Ltd. NICPIR
Piramal Phytocare Ltd. PIRLIF
Ranbaxy Laboratories Ltd. RANLAB
Sanjivani paranteral Ltd. SANPAR
Sarvodaya Labs Ltd. SARLAB
Sun Pharmaceutical Industries Ltd. SUN28
TTK Healthcare Ltd. TTKHEA
Venmax Drugs & Pharmaceuticals Ltd. YENDRU
Venus Remedies Ltd. VENREM
Zenith Healthcare Ltd. ZENHEA
Zenlabs Ethica Ltd. SHRLAK
Zenotech Laboratories Ltd. ZENLAB
Zim Laboratories Ltd. ZIMLAB
Zora Pharma Ltd.[Amalgamated] ZORPHA
Zota Healthcare Ltd. ZOTHEA